A Florbetapir [F18] amyloid PET Imaging study in Parkinson’s disease Dementia (PDD): The influence of amyloid deposition on cognitive status and course of disease progression
Objective: To determine whether amyloid deposition, as assessed by PET imaging with the [18F]-Florbetapir, is related in patients with Parkinson Disease and Dementia (PDD) to…α4β2-nicotinic receptor availability in Parkinson’s disease MCI and healthy controls: A pilot imaging study using [18F]-XTRA PET
Objective: We aimed to show that a radiotracer with high affinity to cortical and hippocampal α4β2-nicotinic cholinergic receptors (1) would be reduced in regions associated…Dopaminergic dysfunction and abnormal metabolic network activity in REM sleep behavior disorder
Objective: This study is to investigate the correlations between the abnormalities in the distribution of striatal dopamine transporter (DAT) and the expression of Parkinson's disease…Imaging of phosphodiesterase 10 A (PDE10A) enzyme levels in the living human brain of Huntington’s disease gene expansion carriers and healthy controls with positron emission tomography.
Objective: The objective of this study was to examine the loss of Phosphodiesterase 10A enzyme (PDE10A) across a broad spectrum of Huntington’s disease (HD) stages.…F-18-DOPA-PET predicts impulsive behavior under dopaminergic therapy in Parkinson patients
Objective: The aim of this study is to investigate the influence of the intensity of dopaminergic projections to the ventral striatum (VS) measured with F-18-DOPA-PET…Clinical characteristics of cognitive impairment in patients with Parkinson’s disease and its related pattern in 18F-FDG PET imaging
Objective: To characterize the clinical features and the neuroanatomical bases of cognitive impairment in Parkinson’s disease (PD) with respect to attention, executive function, memory, language,…Phosphodiesterases and striatal pathways in Parkinson’s disease
Objective: To use phosphodiesterase (PDE)10A ([11C]IMA107) and PDE4 ([11C]Rolipram) positron emission tomography (PET) molecular imaging combined with diffusion tensor imaging (DTI) based probabilistic tractography to explore the expression…Does smoking impact dopamine neuronal loss in de novo Parkinson’s disease?
Objective: To investigate whether smoking impacts striatal dopamine neuronal degeneration in Parkinson’s disease (PD), we compared striatal subregional dopamine transporter (DAT) binding between current-smokers and…Evaluation of SV2A expression with [18F]MNI-944 PET imaging in healthy controls (HC) and Parkinson disease (PD)
Objective: To evaluate [18F]MNI-944, a highly selective synaptic SV2A PET imaging tracer, as a biomarker for longitudinal studies in early PD. Background: PD symptoms manifest…[11C]PK11195 PET Imaging Reveals Neuroinflammation in Dementia with Lewy Bodies: NIMROD Study
Objective: To determine if subjects with dementia with Lewy bodies(DLB) have increased microglial activation in vivo compared to matched healthy controls as assessed using PET…
- « Previous Page
- 1
- …
- 26
- 27
- 28
- 29
- 30
- …
- 35
- Next Page »